Advertisement
2025 ASCO Gastrointestinal Cancers Symposium
Everolimus/Lanreotide vs Everolimus in Gastroenteropancreatic Neuroendocrine Tumors
A recent study found that a combination of the mTOR inhibitor everolimus and the hormone-blocking drug lanreotide extended progression-free survival compared with everolimus alone for people with some...
Does a New Blood-Based Screening Test Accurately Detect Colorectal Cancer Risk?
Colorectal cancer is the second most common cause of cancer-related deaths in the United States. This year, it’s expected that more than 53,000 individuals will die of the disease. Although screening ...
ChatGPT Has Limitations in Clinical Utility for Colorectal Cancer but May Be Useful for Patient Education
A study evaluating ChatGPT’s ability to accurately respond to patient inquiries regarding colon cancer by comparing its responses with assessments from expert clinical oncologists found that questions...
Advertisement
Advertisement
Feb
Today In Oncology08
Advertisement
© 2025 HSP News Service, L.L.C.
